ibuprofen and dabigatran

Ibuprofen inhibits platelet aggregation and can cause gastric mucosal damage, increasing bleeding risk. Additionally, NSAIDs may reduce renal function, decreasing clearance of dabigatran (which is largely excreted renally), thereby increasing its plasma concentration and anticoagulant effect.

Concomitant use significantly increases the risk of serious bleeding, including gastrointestinal haemorrhage, intracranial haemorrhage, and other bleeding complications. The risk is further elevated in patients with pre-existing renal impairment, elderly patients, or those receiving other anticoagulants or antiplatelet agents.

Avoid concomitant use where possible. If short-term analgesia is required, consider alternatives such as paracetamol or a non-NSAID analgesic. If ibuprofen is essential, use the lowest effective dose for the shortest duration, closely monitor for signs of bleeding, and regularly assess renal function.

This interaction is well established based on pharmacodynamic and pharmacokinetic mechanisms, supported by clinical trials and case reports. Guidelines generally advise caution or avoidance of NSAIDs in patients receiving dabigatran due to increased bleeding risk.